Register Login

ALTERITY THERAPEUTICS LIMITED (PRNAF)

SymbolPRNAF
NameALTERITY THERAPEUTICS LIMITED
SectorHEALTH CARE
RegionOceania
Industry-
AddressVIC 3000 Australia Level 3, 460 Bourke Street
Telephone61 452 510 255
Fax—
Email—
Websitehttps://alteritytherapeutics.com/
IncorporationAU
Incorporated On—
Employees—
Fiscal Year6/30
Public Since—
ExchangesOTC;NASDAQ
Auditor—
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001131343
Description

Alterity Therapeutics Limited creates an alternate, healthier life for people living with neurodegenerative diseases.

Additional info from NASDAQ:
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimers disease, Huntington disease, and other neurodegenerative disorders. The companys lead drug candidate-PBT2 is being developed for the treatment of Alzheimers and Huntingtons diseases. It has also advanced a drug candidate for Parkinsons disease and other movement disorders (ATH434).

Additional info from OTC:
Alterity Therapeutics Limited creates an alternate, healthier life for people living with neurodegenerative diseases.

2025-07-24 00:23

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Read more
2025-06-23 02:17

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Read more
2025-05-12 00:01

Alterity Therapeutics Prominently Featured at the International MSA Congress

Read more
2025-05-07 03:08

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Read more
2025-05-04 23:33

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Read more
2025-04-29 02:13

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Read more
2025-04-02 23:20

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

Read more
2025-02-03 01:14

Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities

Read more
2025-01-29 22:29

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Read more
2024-11-05 22:35

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Read more